



Final Appraisal Recommendation
Advice No: 0721 – May 2021

Indacaterol acetate/glycopyrronium bromide/mometasone furoate (Enerzair® Breezhaler®) 114 micrograms/46 micrograms/136 micrograms inhalation powder, hard capsules

Submission by Novartis Pharmaceuticals UK Ltd

Recommendation of AWMSG

Indacaterol acetate/glycopyrronium bromide/mometasone furoate (Enerzair® Breezhaler®) is recommended as an option for use within NHS Wales for the maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Additional note(s):

- AWMSG noted that AWTTTC considered the cost minimisation analysis inappropriate because it was based on a non-inferiority study and not all effects were shown to be equivalent.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3141), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0721:
Indacaterol acetate/glycopyrronium bromide/mometasone furoate (Enerzair® Breezhaler®) 114 micrograms/46 micrograms/136 micrograms inhalation powder, hard capsules. May 2021.

